Arslan Malik
About Arslan Malik
Arslan Malik is the Vice President of Clinical Sciences at Boston Scientific, with extensive experience in clinical research and regulatory affairs across various medical and healthcare organizations.
Title
Arslan Malik currently holds the position of Vice President, Clinical Sciences at Boston Scientific. He assumed this role in 2024.
Professional Background
Arslan Malik has accumulated extensive experience in clinical research and regulatory affairs over his career. Before joining Boston Scientific, he was the Vice President of Clinical & Regulatory Affairs at Reprieve Cardiovascular from 2021 to 2024. Prior to that, he held several significant roles at Medtronic, including Vice President of Clinical Research, Structural Heart in 2021, Senior Clinical Research Director from 2018 to 2021, Clinical Research Director from 2016 to 2018, Senior Clinical Research Manager from 2015 to 2016, and Clinical Program Manager from 2013 to 2015. He also worked as a Clinical Studies Engineer at BIOTRONIK and a Clinical Study Manager at W.L. Gore & Associates. His career began as a Clinical Research Specialist at Mayo Clinic in 2007.
Education and Expertise
Arslan Malik has a strong educational background that supports his extensive career in clinical sciences. He earned a Master of Business Administration (MBA) from the University of Phoenix, studying from 2010 to 2012. He also holds an M.B.B.S. degree from King Edward Medical College, where he studied Medicine from 1997 to 2002.
Roles at Medtronic
Arslan Malik's tenure at Medtronic was marked by various leadership positions. He was the Vice President of Clinical Research, Structural Heart in 2021 and served as the Senior Clinical Research Director from 2018 to 2021. Earlier roles include Clinical Research Director from 2016 to 2018, Senior Clinical Research Manager from 2015 to 2016, and Clinical Program Manager from 2013 to 2015. His responsibilities in these roles involved overseeing clinical research projects and managing clinical programs to advance Medtronic's cardiovascular technologies.